James Mullen, former chief executive officer at Biogen Idec, is the new CEO at contract drug manufacturer Patheon.
Patheon is based in RTP, but its stock trades on the Toronto exchange.
“Mr. Mullen’s extensive pharmaceutical manufacturing background and proven track record of driving growth and profitability give us confidence that, under his leadership, Patheon will be able to realize its full potential as an industry leader,” said Patheon Chairman Ramsey Frank in a statement.
Wesley Wheeler was replaced as Patheon’s CEO in December.
Peter Bigelow, Patheon’s president for North America, served as interim CEO.
Mullen was CEO at Biogen for 10 years. He led the merger with Idce to form one of the world’s largest biotech firms.
Patheon provides contract development and manufacturing services to pharmaceutical and biotech firms wordwide.
Biogen Idec operates a facility in RTP.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
